Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs
← Glossary

LillyDirect

Weight Loss

Eli Lilly's direct-to-consumer cash-pay channel for Zepbound, Mounjaro, and orforglipron.

A manufacturer direct-pay channel that sells branded GLP-1s to cash-pay patients, bypassing pharmacy and PBM markup. Zepbound vials from $349-549/mo, orforglipron $149/mo. Still routes the prescription through a licensed clinician.

We may earn a commission when you click links to partners. Affiliate disclosure.